Last updated: February 16, 2026
What is the current market landscape for NDC 75834-0328?
NDC 75834-0328 refers to the drug Zepzelca (lurbinectedin), developed by PharmaMar. It is an FDA-approved treatment for metastatic small cell lung cancer (SCLC) with progression after platinum-based chemotherapy. The drug received accelerated approval in June 2020 under regulatory pathways designed for oncology drugs with promising early data.
How does Zepzelca compare in the treatment landscape?
- Indication: SCLC post-chemotherapy.
- Competitors: Top competitors include topotecan, lurbinectedin (as part of trials), and emerging therapies incorporating immunotherapies like atezolizumab and durvalumab combined with chemotherapy.
- Market penetration: Limited at launch due to rarity of SCLC and access issues. It has been marketed primarily in the US, with limited international availability.
What are the sales and revenue trends?
- Initial sales: Estimated at approximately $50 million in 2021.
- Growth trajectory: Growth depends on expanding indications and increased market adoption.
- Forecasts: Edge estimates predict peak annual sales reaching $150-200 million within 5 years, contingent on approval in other regions, expanded indications, and clinician adoption.
What factors influence price setting?
- Pricing benchmarks: Similar oncology drugs with accelerated approval, such as Lynparza (olaparib) or Kadcyla (ado-trastuzumab emtansine), have list prices ranging from $8,000 to $15,000 per month.
- Current pricing: Zepzelca's list price is approximately $11,000 per treatment cycle (based on a 28-day cycle with one vial per cycle).
- Insurance coverage: Coverage varies; private insurers and Medicaid programs influence net prices through negotiations.
- Manufacturing costs: Relatively high due to complex synthesis processes of the marine-derived compound.
- Reimbursement rates: Influenced by cost-effectiveness analyses; however, given the rarity of SCLC, premium pricing persists.
What are future price projections?
| Year |
Estimated Price per Cycle |
Rationale |
| 2023 |
$11,000 |
Current list price; minor adjustments due to inflation and cost negotiations |
| 2024 |
$10,800 |
Potential price compression from increased competition and payer negotiations |
| 2025 |
$10,500 |
Market stabilization as trial data expands indications and regional approvals increase |
| 2026 |
$10,000 |
Marginal decline expected with biosimilar or generic entry, unlikely in short-term due to complex chemistry |
| 2027+ |
Stabilizes around $9,500-$10,000 |
Longer-term, price may decline with market evolution, but high manufacturing costs and limited competition may maintain higher prices |
How could market and policy shifts influence prices?
- Regulatory expansions: Approval for earlier lines of therapy or additional indications could boost volume, possibly leading to price adjustments.
- Biosimilar entry: Currently, biosimilars are unlikely given the nature of molecular agents involved.
- Medicare/Medicaid negotiations: Policy shifts aiming at drug price reductions could impact net prices.
- Negotiated discounts: Payers may seek rebates, lowering the effective price, though list price stability is likely.
Summary
Zepzelca (lurbinectedin) remains a niche but clinically relevant agent for small cell lung cancer. Its pricing is aligned with similar oncology agents, around $11,000 per cycle, with limited short-term decline projections barring significant market or policy shifts. Sales are expected to grow modestly, especially as indications expand and regional access increases.
Key Takeaways
- The current list price is approximately $11,000 per cycle, similar to other specialty oncology drugs.
- Peak sales estimates reach $150-200 million annually within five years.
- Significant price reductions are unlikely in the near term due to high manufacturing complexity and limited competition.
- Market growth depends on expanded approval and clinician adoption.
- Policy and reimbursement strategies will impact net prices over the long term.
FAQs
1. How does the pricing of Zepzelca compare to other oncology drugs?
It is comparable to drugs like Lynparza and Kadcyla, which list between $8,000 and $15,000 per month or cycle.
2. What factors could cause Zepzelca’s price to increase?
Increased demand from expanded indications and regional approvals could support stable or slightly increased pricing due to scarcity.
3. What factors could lead to price reductions?
Introduction of biosimilars, policy-driven negotiations, broader use, and improved manufacturing efficiencies could lower net prices.
4. How does regional variability influence prices?
Pricing varies significantly across countries; for example, European prices may be 20-30% lower than US list prices due to regulatory and reimbursement differences.
5. When is peak sales volume expected?
Peak sales could occur within five years if indications expand and access improves, with annual revenue reaching approximately $150-200 million.
Citations
[1] FDA approval announcement for Zepzelca (lurbinectedin): FDA, 2020.
[2] Market research estimates on SCLC treatments: IQVIA, 2022.
[3] Oncology drug pricing data: SSR Health & GOODRX, 2022.
[4] Comparative drug pricing benchmarks: Medicare & private insurer data, 2022.
